A phase I clinical trial of Programmed cell death protein 1 gamma-delta chimeric antigen receptor T cell therapy (Procel™), in combination with a standard anticancer therapy, for the treatment of solid tumours
Latest Information Update: 29 Jun 2022
At a glance
- Drugs Programmed cell death protein 1 gamma-delta chimeric antigen receptor T cell therapy-Kiromic (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kiromic
Most Recent Events
- 29 Jun 2022 New trial record
- 21 Jun 2022 According to a Kiromic Biopharma media release, the company plans to file an IND for Procel™ in combination with standard antitumor modality in 2023 with clinical activation expected in Q2 2023.